• 1
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR, 4th edn. American Psychiatric Association, Washington, DC, 1994.
  • 2
    Naranjo CA, Tremblay LK, Busto UE. The role of the brain reward system in depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2001; 25: 781823.
  • 3
    Treadway MT, Buckholtz JW, Schwartzman AN, Lambert WE, Zald DH. Worth the ‘EEfRT’? The effort expenditure for rewards task as an objective measure of motivation and anhedonia. PLoS ONE 2009; 4: e6598.
  • 4
    Opbroek A, Delgado PL, Laukes C et al. Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses? Int. J. Neuropsychopharmacol. 2002; 5: 147151.
  • 5
    Prince J, Cole V, Goodwin GM. Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study. Br. J. Psychiatry 2009; 195: 211217.
  • 6
    Shelton RC, Tomarken AJ. Can recovery from depression be achieved? Psyichiatr. Serv. 2001; 52: 14691478.
  • 7
    Dickinson A, Balleine B. Motivational control of goal-directed action. Anim. Learn. Behav. 1994; 22: 118.
  • 8
    Roesch MR, Olson CR. Neutral activity related to reward value and motivation in primate frontal cortex. Science 2004; 304: 307310.
  • 9
    Loubinoux I, Pariente J, Boulanouar K et al. A single dose of the serotonin neurotransmission agonist paroxetine enhances motor output: double-blind, placebo-controlled, fMRI study in healthy subjects. NeuroImage 2002; 15: 2636.
  • 10
    Loubinoux I, Pariente J, Rascol O, Celsis P, Chollet F. Selective serotonin reuptake inhibitor paroxetine modulates motor behavior through practice. A double-blind, placebo-controlled, multi-dose study in healthy subjects. Neuropsychologia 2002; 40: 18151821.
  • 11
    Wingen M, Kuypers KP, van de Ven V, Formisano E, Ramaekers JG. Sustained attention and serotonin: a pharmaco-fMRI study. Hum. Psychopharmacol. 2008; 23: 221230.
  • 12
    Del-Ben CM, Deakin JFW, Mckie S et al. The effect of citalopram pretreatment on neuronal responses to neuropsychological tasks in normal volunteers: an fMRI Study. Neuropsychopharmacology 2005; 30: 17241734.
  • 13
    McCabe C, Mishor Z, Cowen PJ, Harmer CJ. Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment. Biol. Psychiatry 2010; 67: 439455.
  • 14
    Barnhart WJ, Makela EH, Latocha MJ. SSRI-induced apathy syndrome: a clinical review. J. Psychiatr. Pract. 2004; 10: 196199.
  • 15
    Hasler G, Drevets WC, Manji HK, Charney DS. Discovering endophenotypes for major depression. Neuropsychopharmacology 2004; 29: 17651781.
  • 16
    Beer MH, Porter RS, Jones TV. The Merck Manual of Diagnosis and Therapy, 18th edn. Merck Sharp & Dohme Corp, Whitehouse Station, 2006.
  • 17
    Knutson B, Adams CM, Fong GW, Hommer D. Anticipation of increasing monetary reward selectively recruits nucleus accumbens. J. Neurosci. 2001; 21 (RC159): 15.
  • 18
    Dillon DG, Holmes AJ, Jahn AL, Bogdan R, Wald LL, Pizzagalli DA. Dissociation of neural regions associated with anticipatory versus consummatory phases of incentive processing. Psychophysiology 2008; 45: 3649.
  • 19
    Knutson B, Taylor J, Kaufman M, Peterson R, Glover G. Distributed neural representation of expected value. J. Neurosci. 2005; 25: 48064812.
  • 20
    Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, Zubieta JK. Individual differences in reward responding explain placebo-induced expectations and effects. Neuron 2007; 55: 325336.
  • 21
    Owens MJ, Morgan WN, Plott SJ, Nemeroff CB. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J. Pharmacol. Exp. Ther. 1997; 283: 13051322.
  • 22
    Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol. Psychiatry 2001; 50: 345350.
  • 23
    Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur. J. Pharmacol. 1997; 340: 249258.
  • 24
    Irie H, Fujita M, Inokawa Y, Narita H. Phase 1 clinical study of paroxetine HCI (Study 3): Pharmacokinetics after single oral administration of paroxetine HCI 10,20 and 40 mg to healthy adult male volunteers. Jpn. Pharmacol. Ther. 2000; 28: S47S68 (in Japanese).
  • 25
    Meyer JH, Wilson AA, Sagrati S et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am. J. Psychiatry 2004; 161: 826835.
  • 26
    Suhara T, Takano A, Sudo Y et al. High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arc. Gen. Psychiatry 2003; 60: 386391.
  • 27
    Ashburner J, Friston KJ. Nonlinear spatial normalization using basis functions. Hum. Brain Mapp. 1999; 7: 254266.
  • 28
    Tanaka S, Doya K, Okada G, Ueda K, Okamoto Y, Yamawaki S. Prediction of immediate and future rewards differentially recruits cortico-basal ganglia loops. Nat. Neurosci. 2004; 7: 887893.
  • 29
    Knutson B, Fong GW, Adams CM, Varner JL, Hommer D. Dissociation of reward anticipation and outcome with event-related fMRI. NeuroReport 2001; 12: 36833687.
  • 30
    Carrillo-de-la-Peña MT, Galdo-Álvarez S, Lastra-Barreira C. Equivalent is not equal: primary motor cortex (MI) activation during motor imagery and execution of sequential movements. Brain Res. 2008; 1226: 134143.
  • 31
    Critchley HD, Mathias CJ, Dolan RJ. Neural activity in the human brain relating to uncertainty and arousal during anticipation. Neuron 2001; 29: 537545.
  • 32
    Cools R, Roberts AC, Robbins TW. Serotoninergic regulation of emotional and behavioural control processes. Trends Cogn. Sci. 2008; 12: 3140.